Seizures – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Seizures – Pipeline Review, H2 2016’, provides an overview of the Seizures pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seizures and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Seizures

The report reviews pipeline therapeutics for Seizures by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Seizures therapeutics and enlists all their major and minor projects

The report assesses Seizures therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Seizures

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Seizures

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adamas Pharmaceuticals, Inc.

Advicenne

Alexza Pharmaceuticals, Inc.

Biscayne Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

Eisai Co., Ltd.

GW Pharmaceuticals Plc

INSYS Therapeutics, Inc.

Lotus Pharmaceutical Co., Ltd.

Marinus Pharmaceuticals, Inc.

Neurelis, Inc.

Novartis AG

OPKO Health, Inc.

Pfizer Inc.

PTC Therapeutics, Inc.

Sage Therapeutics, Inc.

SciFluor Life Sciences, LLC

Shire Plc

SK Biopharmaceuticals Co., Ltd.

Suda Ltd

Turing Pharmaceuticals AG

UCB S.A.

Ultragenyx Pharmaceutical Inc.

Upsher-Smith Laboratories, Inc.

Xenon Pharmaceuticals Inc.

XERIS Pharmaceuticals, Inc.

Zogenix, Inc.

Zynerba Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Seizures Overview 8

Therapeutics Development 9

Pipeline Products for Seizures - Overview 9

Pipeline Products for Seizures - Comparative Analysis 10

Seizures - Therapeutics under Development by Companies 11

Seizures - Therapeutics under Investigation by Universities/Institutes 14

Seizures - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Seizures - Products under Development by Companies 19

Seizures - Products under Investigation by Universities/Institutes 23

Seizures - Companies Involved in Therapeutics Development 24

Adamas Pharmaceuticals, Inc. 24

Advicenne 25

Alexza Pharmaceuticals, Inc. 26

Biscayne Pharmaceuticals, Inc. 27

Catalyst Pharmaceuticals, Inc. 28

Eisai Co., Ltd. 29

GW Pharmaceuticals Plc 30

INSYS Therapeutics, Inc. 31

Lotus Pharmaceutical Co., Ltd. 32

Marinus Pharmaceuticals, Inc. 33

Neurelis, Inc. 34

Novartis AG 35

OPKO Health, Inc. 36

Pfizer Inc. 37

PTC Therapeutics, Inc. 38

Sage Therapeutics, Inc. 39

SciFluor Life Sciences, LLC 40

Shire Plc 41

SK Biopharmaceuticals Co., Ltd. 42

Suda Ltd 43

Turing Pharmaceuticals AG 44

UCB S.A. 45

Ultragenyx Pharmaceutical Inc. 46

Upsher-Smith Laboratories, Inc. 47

Xenon Pharmaceuticals Inc. 48

XERIS Pharmaceuticals, Inc. 49

Zogenix, Inc. 50

Zynerba Pharmaceuticals, Inc. 51

Seizures - Therapeutics Assessment 52

Assessment by Monotherapy Products 52

Assessment by Target 53

Assessment by Mechanism of Action 57

Assessment by Route of Administration 61

Assessment by Molecule Type 63

Drug Profiles 65

ADS-4101 - Drug Profile 65

ADV-6208 - Drug Profile 66

ADV-6770 - Drug Profile 67

alprazolam - Drug Profile 68

AMPX-0079 - Drug Profile 70

ataluren - Drug Profile 71

BIS-001 - Drug Profile 79

brivaracetam - Drug Profile 80

cannabidiol - Drug Profile 84

cannabidiol - Drug Profile 90

CCG-63802 - Drug Profile 92

CHEC-9 - Drug Profile 93

clobazam - Drug Profile 94

CNSA-004 - Drug Profile 95

CPP-115 - Drug Profile 96

CUR-1916 - Drug Profile 100

diazepam - Drug Profile 101

diazepam - Drug Profile 103

everolimus - Drug Profile 104

fenfluramine hydrochloride - Drug Profile 115

fosphenytoin sodium - Drug Profile 118

ganaxolone - Drug Profile 119

lacosamide - Drug Profile 124

levetiracetam - Drug Profile 133

levetiracetam ER - Drug Profile 136

lorazepam - Drug Profile 137

LSPGR-1 - Drug Profile 138

magnesium valproate hydrate - Drug Profile 139

MB-003 - Drug Profile 140

midazolam hydrochloride - Drug Profile 141

midazolam hydrochloride - Drug Profile 144

midazolam hydrochloride - Drug Profile 145

midazolam hydrochloride - Drug Profile 146

Oligonucleotide for Dravet Syndrome - Drug Profile 147

perampanel - Drug Profile 148

pregabalin - Drug Profile 155

SAGE-217 - Drug Profile 159

SAGE-689 - Drug Profile 161

selurampanel - Drug Profile 162

sepranolone - Drug Profile 163

SF-0034 - Drug Profile 170

Small Molecule for Stroke and Epilepsy - Drug Profile 172

Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 173

Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile 174

Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 175

Small Molecules for Seizure Disorders - Drug Profile 176

Small Molecules for Seizures - Drug Profile 177

TG-4155 - Drug Profile 178

TRP-001 - Drug Profile 179

TUR-004 - Drug Profile 180

TUR-005 - Drug Profile 181

UX-007 - Drug Profile 182

YKP-3089 - Drug Profile 187

ZYN-002 - Drug Profile 189

Seizures - Dormant Projects 192

Seizures - Discontinued Products 195

Seizures - Product Development Milestones 196

Featured News & Press Releases 196

Appendix 209

Methodology 209

Coverage 209

Secondary Research 209

Primary Research 209

Expert Panel Validation 209

Contact Us 209

Disclaimer 210

List of Tables

List of Tables

Number of Products under Development for Seizures, H2 2016 13

Number of Products under Development for Seizures – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Development, H2 2016 21

Comparative Analysis by Unknown Stage Development, H2 2016 22

Products under Development by Companies, H2 2016 23

Products under Development by Companies, H2 2016 (Contd..1) 24

Products under Development by Companies, H2 2016 (Contd..2) 25

Products under Development by Companies, H2 2016 (Contd..3) 26

Products under Investigation by Universities/Institutes, H2 2016 27

Seizures – Pipeline by Adamas Pharmaceuticals, Inc., H2 2016 28

Seizures – Pipeline by Advicenne, H2 2016 29

Seizures – Pipeline by Alexza Pharmaceuticals, Inc., H2 2016 30

Seizures – Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016 31

Seizures – Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016 32

Seizures – Pipeline by Eisai Co., Ltd., H2 2016 33

Seizures – Pipeline by GW Pharmaceuticals Plc, H2 2016 34

Seizures – Pipeline by INSYS Therapeutics, Inc., H2 2016 35

Seizures – Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016 36

Seizures – Pipeline by Marinus Pharmaceuticals, Inc., H2 2016 37

Seizures – Pipeline by Neurelis, Inc., H2 2016 38

Seizures – Pipeline by Novartis AG, H2 2016 39

Seizures – Pipeline by OPKO Health, Inc., H2 2016 40

Seizures – Pipeline by Pfizer Inc., H2 2016 41

Seizures – Pipeline by PTC Therapeutics, Inc., H2 2016 42

Seizures – Pipeline by Sage Therapeutics, Inc., H2 2016 43

Seizures – Pipeline by SciFluor Life Sciences, LLC, H2 2016 44

Seizures – Pipeline by Shire Plc, H2 2016 45

Seizures – Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 46

Seizures – Pipeline by Suda Ltd, H2 2016 47

Seizures – Pipeline by Turing Pharmaceuticals AG , H2 2016 48

Seizures – Pipeline by UCB S.A., H2 2016 49

Seizures – Pipeline by Ultragenyx Pharmaceutical Inc., H2 2016 50

Seizures – Pipeline by Upsher-Smith Laboratories, Inc., H2 2016 51

Seizures – Pipeline by Xenon Pharmaceuticals Inc., H2 2016 52

Seizures – Pipeline by XERIS Pharmaceuticals, Inc., H2 2016 53

Seizures – Pipeline by Zogenix, Inc., H2 2016 54

Seizures – Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 55

Assessment by Monotherapy Products, H2 2016 56

Number of Products by Stage and Target, H2 2016 58

Number of Products by Stage and Mechanism of Action, H2 2016 62

Number of Products by Stage and Route of Administration, H2 2016 66

Number of Products by Stage and Molecule Type, H2 2016 68

Seizures – Dormant Projects, H2 2016 196

Seizures – Dormant Projects (Contd..1), H2 2016 197

Seizures – Dormant Projects (Contd..2), H2 2016 198

Seizures – Discontinued Products, H2 2016 199

List of Figures

List of Figures

Number of Products under Development for Seizures, H2 2016 13

Number of Products under Development for Seizures – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Products, H2 2016 21

Assessment by Monotherapy Products, H2 2016 56

Number of Products by Top 10 Targets, H2 2016 57

Number of Products by Stage and Top 10 Targets, H2 2016 57

Number of Products by Top 10 Mechanism of Actions, H2 2016 61

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 61

Number of Products by Top 10 Routes of Administration, H2 2016 65

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 65

Number of Products by Molecule Types, H2 2016 67

Number of Products by Stage and Molecule Types, H2 2016 67

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports